Tuesday 4 June 2013
European Medicines Agency recommends approval of pomalidomide
The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Pomalidomide Celgene intended for the treatment of multiple myeloma. Read more here.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment